Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?

[powerpress]

The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on their tumor. Should we be using this as a biomarker?

[powerpress]

Research released at the 2015 American Society of Clinical Oncology (ASCO) annual meeting showed great promise for squamous cell lung cancer patients taking the immunotherapy drug Opdivo (nivolumab). But can we predict which patients will do well on it?

[powerpress]

Acquired Resistance Forum Video #14: Speakers from video #11 and video #12 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.

Acquired Resistance Forum Video #13: Dr. Jack West of Swedish Cancer Institute discussed how the skyrocketing costs of cancer care are impacting whether or not some patients are able to get the right treatments.

[powerpress]

November is Lung Cancer Awareness Month. To mark it this year, GRACE is celebrating the empowered lung cancer patient. In this video, Dr. Jack West, GRACE founder and president, explains the steps that patients can do to become empowered.

Dr. Jack West, Dr. Julie Brahmer, and Dr. Ben Creelan discuss the excitement the medical community is feeling about immunotherapy for the treatment of lung cancer. February 2014

[powerpress]

Drs. Nasser Hanna and Melissa Johnson discuss developments in Immunotherapy since ASCO 2013.

[powerpress]

Drs. Nasser Hanna and Melissa Johnson discuss new trial evidence for the use of adjuvant Erlotinib for early-stage lung cancer.

[powerpress]

Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.

[powerpress]